PBM Impact On Off-Patent Industry Condemned At Senate Hearing

Discussion Before US Senate Finance Committee Has Been Praised By The Biosimilars Forum

Witnesses at a US Senate Finance Committee Hearing have condemned the impact the “perverse” practices of pharmacy benefit managers have on off-patent drugs, often placing them on non-preferred tiers so that patients must use more expensive, branded medication.

100 dollar bill surrounded by white capsules
PBM practices make it harder for patients to acquire cheaper off-brand medication • Source: Shutterstock

Pharmacy benefit managers found themselves under the microscope at a recent hearing of the US Senate Committee on Finance, as academics, legal experts and industry stakeholders examined the impact the business practices of these organizations have on the wider healthcare ecosystem.

Led by senators Ron Wyden, D-OR, who chairs the Senate Finance Committee, and Mike Crapo, R-ID, the hearing received testimony...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Drug Pricing

More from Policy & Regulation

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Policy&Regulation-Free: Article with different widgets

    Emerging CRISPR innovations, shifting regulatory landscapes, and rising partnerships are accelerating a paradigm shift in biotech pipelines

  • Overseas API Manufacturing Identified As Key Vulnerability In US Supply Chain

    After US President Joe Biden launched a review of the country’s API supply chain, the task force has reported back with key vulnerabilities that contribute to drug shortages and supply risks during a global public health emergency. According to the report, the lack of geographic diversity and dependence on foreign nations and anti-competitive actions by foreign nations are key areas of concern.